Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, ...

AstraZeneca's full-year 2025 results are due on 10 February. Learn what investors should watch including Tagrisso sales, ...

AstraZeneca secured a Federal Court injunction in Australia blocking Pharmacor from selling generic dapagliflozin while a ...

AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the ...

The company's shares rose 11% in the fourth quarter to close at 137.90 pounds on Dec. 31.

AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.

AstraZeneca CEO Pascal Soriot on Tuesday reiterated the pharmaceutical firm's commitment to the U.S. market amid reports that he is considering shifting its listing stateside. Stream Los Angeles News ...

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his final trade. On Aug. 20, AstraZeneca released complete results from the ...

In a report released today, Matthew Weston from UBS maintained a Buy rating on AstraZeneca, with a price target of £163.00. Weston covers the Healthcare sector, focusing on stocks such as Novo Nordisk ...

Astrazeneca (AZN) ended the recent trading session at $184.32, demonstrating a -2.17% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.84%. On the other ...